Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 8/20 | 0.49 |
| ▸ | KLK7 | P49862 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5050482 | 0.88 | MEN1 (0.47) | CTRB1MEN1KMT2ANPC1LMNA | |
| SCHEMBL2072188 | 0.86 | CTSC (0.53) | CTRB1MEN1KMT2AACENPC1 | |
| SCHEMBL2072191 | 0.86 | CTSC (0.53) | CTRB1MEN1KMT2AACENPC1 | |
| SCHEMBL10584420 | 0.86 | CTRB1 (0.71) | CTRB1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL21748404 | 0.86 | CMA1 (0.63) | CTRB1MEN1KMT2AACEKLK5 | |
| SCHEMBL3825215 | 0.86 | CMA1 (0.63) | CTRB1MEN1KMT2AACEKLK5 | |
| SCHEMBL3165695 | 0.86 | CMA1 (0.63) | CTRB1MEN1KMT2AACEKLK5 | |
| SCHEMBL3165688 | 0.86 | CMA1 (0.63) | CTRB1MEN1KMT2AACEKLK5 | |
| SCHEMBL10478071 | 0.86 | CTRB1 (0.71) | CTRB1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL28067687 | 0.84 | ACE (0.56) | CTRB1MEN1KMT2AACEKLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368424-B2 | Acylated nonadepsipeptides | AICURIS GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | BAYER HEALTHCARE AG (DE) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | VIP, LNPEP, HAMP | CTRB1 448/4885MEN1 841/4885KMT2A 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.